From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates

Labcorp Oncology's Medical Affairs Team explore the evolving role of HER2 overexpression in various solid tumors and discuss how advancements in Antibody Drug Conjugates, particularly T-DXd, are transforming treatment strategies in solid malignancies. They also highlight the challenges in HER2 testing across pan-solid tumors and the potential of NGS and AI algorithms to enhance diagnostic accuracy.

Graphical Summary: A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors

Key TakeawaysOur GIA calls aligned well with reference populations of inferred ancestries, were highly concordant with SIRE (95%), and could expand upon SIRE by detecting ancestries missing appropriate SIRE groups.Accurate GIA provides essential data to support ancestryaware biomarker research, promote the inclusion of underrepresented groups in clinical studies, and enhance diverse representation in precision clinical trials.

Join Labcorp in Chicago

American Association for Cancer Research® (AACR) Annual Meeting 2025

Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1

Investigators from Illumina and Labcorp medical affairs teamed up to perform the largest real-world characterization of advanced non-small cell lung cancer using the TruSight® Oncology 500 (TSO500) assay to date. In our recently published manuscript in Frontiers, we assessed the spectrum of current FDA therapy-associated and clinical trial-associated genomic variants, along with known and novel patterns of co-mutations and co-occurrence with biomarkers predictive of immunotherapy response. We retrospectively analyzed clinical TSO 500 testing data from 7,606 NSCLC  biopsy specimens submitted for testing during standard clinical care. Our data provides further characterization of NSCLC at the genomic and immune checkpoint inhibitor response biomarker level and highlights the clinical utility of broad coverage CGP testing in detecting both known and novel facets of NSCLC to inform treatment decision-making.